Close
Nordic 9Nordic 9

aMoon (investor - Venture Capital)

Israel amoon.fund
See something wrong or missing? Let us know
Offices:Tel Aviv

aMoon is an Israel-based healthtech and life sciences venture fund

Average round investment:67.19M USD
Average number per year:1.3
Distribution: 2025 (1)2024 (1)2020 (2)
Portfolio companies: Netherlands AdcytherixSwitzerland LyfegenSwitzerland Sophia Genetics See the entire list
Mostly invests in: Switzerland Switzerland (2) Health services (4)
See the entire list

Showing 3 of 4 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to aMoon

Name Criteria
United States Bristol-Myers Squibb
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
Belgium Gimv
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 2.0
Germany Hitachi Ventures
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services, Big Data
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom
  • Average number of deals per year: 2.0
United States OrbiMed Advisors
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services, Big Data
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
United States Pfizer Venture Investments
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services, Big Data
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom
  • Average number of deals per year: 2.0
France Sanofi Ventures
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
Canada Georgian
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Software Services, Big Data
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
United States Cargill
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 2.0
United Kingdom SV Health Investors
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
United States Cleveland Avenue
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Software Services, Big Data
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
Top